Simplified Analogs of (-)-Englerin A for Renal Cancer Treatment ID: 2017-027
This technology simplifies the synthesis of (-)-Englerin A analogs, maintaining anti-cancer potency with increased synthetic efficiency.
Photo by Sebastian Kaulitzki - stock.adobe.com
Technology Overview
The document discusses the development of des-CH2 Englerin A (DME), a simplified analog of (-)-Englerin A, which retains the structural integrity and anti-cancer potency of the original compound. This research aims at improving the synthetic efficiency of producing potent inhibitors against renal cancer cells, utilizing a novel streamlined synthetic method.
Key Advantages
- Retains the potent anti-cancer efficacy of (-)-Englerin A against renal cancer cells
- Significantly simplifies the synthesis process, reducing steps from 15-20 to just nine
- Utilizes inexpensive starting materials, lowering production costs
- Achieves a near-complete structural overlay with the original compound, ensuring maintained activity
Problems Addressed
- Complexity and high cost of synthesizing (-)-Englerin A
- Limited availability of potent renal cancer treatments
- Need for more efficient production methods for anticancer agents
Market Applications
- Pharmaceuticals: Development of new renal cancer treatments
- Research and Development: Creation of novel anticancer agents
- Healthcare: Improved treatment options for renal cancer patients
Additional Information
Technology ID: 2017-027
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report